Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.

Sixty-six outpatients with active ulcerative colitis who were intolerant of sulphasalazine were treated in a double-blind randomized trial with placebo or olsalazine in daily doses of 0.75, 1.5, or 3 g. Overall, 35% of patients receiving olsalazine improved clinically, compared to 16% of patients receiving placebo. Statistically significant or nearly significant improvement was demonstrated in colitis activity by the end compared to the beginning of the study within the combined olsalazine group and within patient groups receiving olsalazine at daily doses of 1.5 g and 3 g. There were no differences between the treatment and placebo groups for any of the reported adverse effects or laboratory variables. The data suggest that olsalazine is effective for the treatment of ulcerative colitis and is well tolerated among patients intolerant to sulphasalazine.

[1]  W. Kraaz,et al.  Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. , 1986, Gastroenterology.

[2]  C. H. Mason,et al.  Olsalazine in active ulcerative colitis. , 1985, British medical journal.

[3]  J. V. van Rossum,et al.  Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease. , 1985, Gastroenterology.

[4]  M. Peppercorn.  Sulfasalazine: Pharmacology, Clinical Use, Toxicity, and Related New Drug Development , 1984 .

[5]  J. Rask-Madsen,et al.  Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. , 1984, Gastroenterology.

[6]  P. Cann,et al.  EXACERBATION OF DIARRHOEA AND PAIN IN PATIENTS TREATED WITH 5-AMINOSALICYLIC ACID FOR ULCERATIVE COLITIS , 1984, The Lancet.

[7]  S. Bentley,et al.  Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps. , 1983, British medical journal.

[8]  S. Bondesen,et al.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man. , 1983, British journal of clinical pharmacology.

[9]  R. Allan Reese,et al.  Practical Nonparametric Statistics , 1983 .

[10]  G. Järnerot,et al.  Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. , 1983, Scandinavian journal of gastroenterology.

[11]  J. Sircar,et al.  Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. , 1983, Biochemical pharmacology.

[12]  J. Aronson,et al.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. , 1982, Gut.

[13]  J. Barrowman,et al.  Hair loss and 5-aminosalicylic acid enemas. , 1982, Annals of internal medicine.

[14]  G. Labó,et al.  TREATMENT OF ULCERATIVE COLITIS WITH HIGH-DOSE 5-AMINOSALICYLIC ACID ENEMAS , 1981, The Lancet.

[15]  K Heinkel,et al.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. , 1980, The New England journal of medicine.

[16]  J. V. van Tongeren,et al.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. , 1980, Gut.

[17]  James H. Torrie,et al.  Principles and procedures of statistics: a biometrical approach (2nd ed) , 1980 .

[18]  S. Truelove,et al.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. , 1980, Gut.

[19]  U. Zor,et al.  Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. , 1978, Gastroenterology.

[20]  John Bibby,et al.  The Analysis of Contingency Tables , 1978 .

[21]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[22]  K. Das,et al.  Clinical Pharmacokinetics of Sulphasalazine , 1976, Clinical pharmacokinetics.

[23]  C. Spicer,et al.  Assessment of severity in colitis: a preliminary study. , 1975, Gut.

[24]  J. McManus,et al.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. , 1973, The New England journal of medicine.

[25]  M. Peppercorn,et al.  Distribution studies of salicylazosulfapyridine and its metabolites. , 1973, Gastroenterology.

[26]  H. Schröder,et al.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man , 1972, Clinical pharmacology and therapeutics.

[27]  I. Calder,et al.  Nephrotoxic Lesions from 5-Aminosalicylic Acid , 1972, British medical journal.

[28]  R. Carpenter,et al.  Controlled trial of sulphasalazine in the treatment of ulcerative colitis , 1964, Gut.

[29]  J. H. Baron,et al.  Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. , 1962, Lancet.

[30]  F. Jones,et al.  An Assessment of Prednisone, Salazopyrin, and Topical Hydrocortisone Hemisuccinate Used as Out-patient Treatment for Ulcerative Colitis , 1960, Gut.

[31]  B. Morson,et al.  Crohn's Disease (Regional Enteritis) of the Large Intestine and its Distinction from Ulcerative Colitis , 1960, Gut.

[32]  W. Cant.  On Two Cases of Severe Injury to the Eye* , 1883, British medical journal.